Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 10:53:101284.
doi: 10.1016/j.lanepe.2025.101284. eCollection 2025 Jun.

Safety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): a multicentre, single-arm clinical trial

Remon Korenblik  1   2 Sinéad James  1   2 Jens Smits  1   2 Rafael Díaz-Nieto  3 Rob Davis  4 Benjamin K Y Chan  3 Joris I Erdmann  5 IJsbrand A J Zijlstra  6 Pieter J W Arntz  6 Otto Kollmar  7 Martin H Hoffmann  8 David G Vass  9 Richard Lindsay  10 Matteo Serenari  11   12 Alberto Cappelli  13 Paul D Gobardhan  14 Farshad Imani  15 Yiliam Fundora Suarez  16 Fernando Gómez Muños  17 Dirk J Grünhagen  18 Adriaan Moelker  19 Kay J Pieterman  19 Jörg Kleeff  20 Walter A Wohlgemuth  21 Eric Herrero  22 Arantxa Gelabert  23   24 Stefan Breitenstein  25 Nico Seeger  25 Olivier Detry  26 Laurent Gerard  27 Per A Sandström  28 Bergthor Björnsson  28 Luca A Aldrighetti  29 Francesco De Cobelli  30 Wouter K G Leclercq  31 Laurens J van Baardewijk  32 Daniel Croagh  33   34 Diederick W De Boo  35   34 T Peter Kingham  36 Fourat Ridouani  37 Peter Metrakos  38 David Valenti  39 Jennifer Kalil  38 Åsmund A Fretland  40 Ulrik Carling  41 Guillaume Martel  42 Stephen Ryan  43 Venkatesha Udupa  44 Andrew Macdonald  45 Jordan C Tasse  46 Gregor A Stavrou  47 Elmar Spuentrup  48 Francisco G Borobia  49 Eva Criado  50 Ernesto Sparrelid  51 Martin Delle  52 Jordi Navinés-López  53 Jaume Sampere Moragues  54 Esteban Cugat Andorrà  53 Andreas Schnitzbauer  55 Thomas J Vogl  56 Jan Heil  57 John N Primrose  58 Sachin Modi  59 Suomi M G Fouraschen  60 Reinoud P H Bokkers  61 Marieke T de Boer  60 Inne H M Borel Rinkes  62 Maarten L J Smits  63 Thomas Gruenberger  64   65 Ivan Baclija  66 Kevin G Billingsley  67 David C Madoff  68 Alejandro Serrablo  69 Luis Sarriá  70 Xiaoying Wang  71 Qu Xudong  72 Bjorn Winkens  73 Steven W L Olde Damink  1 Marc H A Bemelmans  1 Maxime J L Dewulf  1 Christoph A Binkert  74 Erik Schadde  75   76 Christiaan van der Leij  2   77 Ronald M van Dam  1   2 DRAGON collaborative study group
Collaborators, Affiliations

Safety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): a multicentre, single-arm clinical trial

Remon Korenblik et al. Lancet Reg Health Eur. .

Abstract

Background: Major liver resection is often required for complete clearance of colorectal liver metastases (CRLM). Patients with insufficient future liver remnant (FLR) volume/function are at high risk of post-hepatectomy liver failure (PHLF) and require FLR hypertrophy-inducing procedures to enable safe resection. The most recent variant of these procedures is combined portal and hepatic vein embolization (PVE/HVE). The DRAGON 1 trial evaluates the safety and efficacy of PVE/HVE, while assessing recruitment potential for the DRAGON 2 randomized trial.

Methods: DRAGON 1 is a prospective, single-arm, international, multicenter trial. Patients with upfront unresectable CRLM due to a small FLR were included. The primary outcome was the ability of centers to recruit three patients and perform PVE/HVE and liver resection without 90-day mortality. Secondary outcomes included recruitment capacity, PVE/HVE technical details, FLR volume changes, complications, and resection rates. The study is registered at ClinicalTrials.gov, identifier: NCT04272931.

Findings: In total, 102 patients were included from 43 centers. Twenty-four centers (24/43 = 56%) recruited three or more patients, and 20 centers (20/43 = 47%) achieved this without 90-day mortality. Of 96 patients undergoing PVE/HVE, no post-embolization mortality occurred, though major complications were reported in two patients. Resection was completed in 86 patients (86/96 = 90%), with seven patients (7/86 = 8%) dying within 90 days. PHLF grade B/C (International Study Group of Liver Surgery criteria) occurred in 19 patients (19/86 = 22%).

Interpretation: DRAGON 1 demonstrates that PVE/HVE is safe, with no embolization-related mortality, low morbidity, and high resection rates in upfront unresectable CRLM.

Funding: The Dutch Cancer Society, National Institute for Health and Care Research UK, Maastricht UMC+, Abbott Laboratories and Guerbet.

Keywords: Bilobar colorectal liver metastases; Colorectal liver metastases; DRAGON 1 trial; Embolization techniques; Extended liver resection; FLR hypertrophy; Future liver remnant; Hepatic regeneration; Hepatic vein embolization; Kinetic growth rate; Liver resection; Liver surgery complications; Liver venous deprivation; Multicenter clinical trial; Portal vein embolization; Post-hepatectomy liver failure; Preoperative liver augmentation; Regenerative liver procedures; Resection rates; Surgical oncology.

PubMed Disclaimer

Conflict of interest statement

C.A. Binkert: research support from Abbott Laboratories; consulting fees from CTI Vascular, Biotronic (consulting on technology). Å.A. Fretland: honoraria from Bayer, Angiodynamics, Medtronic (speaker). D.C. Madoff: Receipt of equipment from Abbott Laboratories (plugs), Guerbet (lipiodol), Boston Scientific (embolic particles) for pre-clinical animal studies; consulting fees from Guerbet, Boston Scientific (advisory board). G. Martel: unrelated research grants from Canadian Institutes of Health Research, Canadian Blood Services. R.M. van Dam: research grants and study materials from Abbott Laboratories, Guerbet.

Figures

Fig. 1
Fig. 1
Flow diagram of patients included. Footnote: FLR: future liver remnant; PVE/HVE: combined portal and hepatic vein embolization.
Fig. 2
Fig. 2
Volume kinetics. Footnote: Changes in standardized FLR (sFLR%) after combined portal and hepatic vein embolization (PVE/HVE). a. Volume kinetics of all 96 patients that underwent PVE/HVE; b. Volume kinetics of the 70 remaining patients not yet planned for resection at week 3, the 26 patients that were planned for resection after week 1 are excluded; c. Volume kinetics of the 24 remaining patients not yet planned for resection at week 6, the additional 46 patients that were planned for resection after week 3 are also excluded.

References

    1. Regimbeau J.M., Cosse C., Kaiser G., et al. Feasibility, safety and efficacy of two-stage hepatectomy for bilobar liver metastases of colorectal cancer: a LiverMetSurvey analysis. HPB (Oxford) 2017;19(5):396–405. - PubMed
    1. Sandstrom P., Rosok B.I., Sparrelid E., et al. ALPPS improves resectability compared with Conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a scandinavian multicenter randomized controlled trial (LIGRO trial) Ann Surg. 2018;267(5):833–840. - PMC - PubMed
    1. Passot G., Chun Y.S., Kopetz S.E., et al. Predictors of safety and efficacy of 2-stage hepatectomy for bilateral colorectal liver metastases. J Am Coll Surg. 2016;223(1):99–108. - PMC - PubMed
    1. Filmann N., Walter D., Schadde E., et al. Mortality after liver surgery in Germany. Br J Surg. 2019;106(11):1523–1529. - PubMed
    1. Wang K., Liu Y., Hao M., et al. Clinical outcomes of parenchymal-sparing versus anatomic resection for colorectal liver metastases: a systematic review and meta-analysis. World J Surg Oncol. 2023;21(1):241. - PMC - PubMed

Associated data